Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $749667.0.

  • Lipocine's Accumulated Expenses fell 4198.9% to $749667.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $749667.0, marking a year-over-year decrease of 4198.9%. This contributed to the annual value of $921240.0 for FY2024, which is 2439.47% down from last year.
  • Latest data reveals that Lipocine reported Accumulated Expenses of $749667.0 as of Q3 2025, which was down 4198.9% from $685779.0 recorded in Q2 2025.
  • In the past 5 years, Lipocine's Accumulated Expenses ranged from a high of $1.6 million in Q3 2021 and a low of $567901.0 during Q1 2022
  • Moreover, its 5-year median value for Accumulated Expenses was $1.1 million (2022), whereas its average is $1.1 million.
  • In the last 5 years, Lipocine's Accumulated Expenses soared by 10383.96% in 2021 and then crashed by 6226.34% in 2022.
  • Quarter analysis of 5 years shows Lipocine's Accumulated Expenses stood at $1.0 million in 2021, then grew by 6.03% to $1.1 million in 2022, then increased by 13.06% to $1.2 million in 2023, then fell by 24.39% to $921240.0 in 2024, then decreased by 18.62% to $749667.0 in 2025.
  • Its last three reported values are $749667.0 in Q3 2025, $685779.0 for Q2 2025, and $619410.0 during Q1 2025.